Impact Of Topical Roaccutane On The Ocular Surface: A Case Report

Published 2026 - 44th Congress of the ESCRS

Reference: POCOR436 | Type: Poster | DOI: 10.82333/1w1r-w062

Authors: A/Prof. Nacima Benmerzouga* ¹

¹faculty of medicine,annaba,Algeria

Purpose

To assess the impact of topical Roaccutane on ocular surface health: a case report

Setting

ophthalmology departement university hospital of Annaba, Annaba, ALGERIA.

Methods

A single patient using topical Roaccutane was evaluated for ocular surface changes. A comprehensive ophthalmological examination, including slit-lamp evaluation, complete ocular surface evaluation, OSDI evaluation, and tear film assessment, was performed.

The protocol consisted of a topical treatment with tear substitutes containing hyaluronic acid, corticstroids eyedrops as well as cyclosporine A eye drops. The patient was followed until complete healing.

Results

he patient presented with a red, painful eye for several weeks, unresponsive to topical treatment. Examination revealed inferior peripheral limbal infiltrates with corresponding stromal edema, superficial punctate keratitis, and dilation of the limbal vessels.

The patient received high-dose dexamethasone eye drops for 15 days, in combination with 2% cyclosporine A and hyaluronic acid eye drops. Clinical improvement was observed, and the patient was referred to a dermatologist for therapy adjustment and isotretinoin discontinuation

Conclusions

Topical Roaccutane may be associated with peripheral corneal inflammation and ocular surface alterations. Careful ophthalmologic monitoring is recommended during treatment to detect and manage potential adverse effects early